Fig. 6: MiRNAs-449 overexpression sensitizes to doxorubicin through ACSL4 downregulation.

ACSL4 expression was analyzed by RT-qPCR (mean ± SD) (n = 3) (A) and Western blot (B) in MDA-MB-231, MDA-MB-436, and MDA-MB-231R cell lines after doxorubicin treatment (1 µM, 48 h). Cell cytotoxicity was analyzed by WST-1 to determine the IC50 value (mean ± SD) (n = 3). MDA-MB-231, MDA-MB-436, and MDA-MB-231R cell lines were transfected with miRNAs-449 mimics (C), siACSL4#1 (D), or siACSL4#2 (E), and different doses of doxorubicin. *p < 0.0500, **p < 0.01, ***p < 0.001, ****p < 0.0001. DOX; doxorubicin.